Role of ErbB4 in breast cancer

Maria Sundvall; Kristiina Iljin; Sami Kilpinen; Henri Sara; Olli-Pekka Kallioniemi; Klaus Elenius

doi:10.1007/s10911-008-9079-3

Role of ErbB4 in breast cancer

Maria Sundvall
, Kristiina Iljin
, Sami Kilpinen
, Henri Sara
, Olli-Pekka Kallioniemi
, Klaus Elenius^*

^*Corresponding author for this work

Turku University Hospital
University of Turku
Institute for Molecular Medicine Finland (FIMM)
University of Helsinki
Åbo Akademi University
VTT (former employee or external)

Research output: Contribution to journal › Article › Scientific › peer-review

117 Citations (Scopus)

Abstract

Members of the ErbB subfamily of receptor tyrosine kinases are important regulators of normal mammary gland physiology, and aberrations in their signaling have been associated with breast tumorigenesis. Therapeutics targeting epidermal growth factor receptor (EGFR = ErbB1) or ErbB2 in breast cancer have been approved for clinical use. In contrast, relatively little is known about the biological significance of ErbB4 signaling in breast cancer. This review focuses on recent advances in our understanding about the role of ErbB4 in breast carcinogenesis, as well as in the potential clinical relevance of ErbB4 in breast cancer prognostics and therapy.

Original language	English
Pages (from-to)	259-268
Journal	Journal of Mammary Gland Biology and Neoplasia
Volume	13
Issue number	2
DOIs	https://doi.org/10.1007/s10911-008-9079-3
Publication status	Published - 2008
MoE publication type	A1 Journal article-refereed

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Alternative splicing
Epidermal growth factor
Estrogen receptor
HER4
Neuregulins
Targeted therapeutics

Access to Document

10.1007/s10911-008-9079-3

Cite this

@article{5394334f01004d43b5d84cd3d419d13b,

title = "Role of ErbB4 in breast cancer",

abstract = "Members of the ErbB subfamily of receptor tyrosine kinases are important regulators of normal mammary gland physiology, and aberrations in their signaling have been associated with breast tumorigenesis. Therapeutics targeting epidermal growth factor receptor (EGFR = ErbB1) or ErbB2 in breast cancer have been approved for clinical use. In contrast, relatively little is known about the biological significance of ErbB4 signaling in breast cancer. This review focuses on recent advances in our understanding about the role of ErbB4 in breast carcinogenesis, as well as in the potential clinical relevance of ErbB4 in breast cancer prognostics and therapy.",

keywords = "Alternative splicing, Epidermal growth factor, Estrogen receptor, HER4, Neuregulins, Targeted therapeutics",

author = "Maria Sundvall and Kristiina Iljin and Sami Kilpinen and Henri Sara and Olli-Pekka Kallioniemi and Klaus Elenius",

year = "2008",

doi = "10.1007/s10911-008-9079-3",

language = "English",

volume = "13",

pages = "259--268",

journal = "Journal of Mammary Gland Biology and Neoplasia",

issn = "1083-3021",

publisher = "Springer",

number = "2",

}

TY - JOUR

T1 - Role of ErbB4 in breast cancer

AU - Sundvall, Maria

AU - Iljin, Kristiina

AU - Kilpinen, Sami

AU - Sara, Henri

AU - Kallioniemi, Olli-Pekka

AU - Elenius, Klaus

PY - 2008

Y1 - 2008

N2 - Members of the ErbB subfamily of receptor tyrosine kinases are important regulators of normal mammary gland physiology, and aberrations in their signaling have been associated with breast tumorigenesis. Therapeutics targeting epidermal growth factor receptor (EGFR = ErbB1) or ErbB2 in breast cancer have been approved for clinical use. In contrast, relatively little is known about the biological significance of ErbB4 signaling in breast cancer. This review focuses on recent advances in our understanding about the role of ErbB4 in breast carcinogenesis, as well as in the potential clinical relevance of ErbB4 in breast cancer prognostics and therapy.

AB - Members of the ErbB subfamily of receptor tyrosine kinases are important regulators of normal mammary gland physiology, and aberrations in their signaling have been associated with breast tumorigenesis. Therapeutics targeting epidermal growth factor receptor (EGFR = ErbB1) or ErbB2 in breast cancer have been approved for clinical use. In contrast, relatively little is known about the biological significance of ErbB4 signaling in breast cancer. This review focuses on recent advances in our understanding about the role of ErbB4 in breast carcinogenesis, as well as in the potential clinical relevance of ErbB4 in breast cancer prognostics and therapy.

KW - Alternative splicing

KW - Epidermal growth factor

KW - Estrogen receptor

KW - HER4

KW - Neuregulins

KW - Targeted therapeutics

U2 - 10.1007/s10911-008-9079-3

DO - 10.1007/s10911-008-9079-3

M3 - Article

SN - 1083-3021

VL - 13

SP - 259

EP - 268

JO - Journal of Mammary Gland Biology and Neoplasia

JF - Journal of Mammary Gland Biology and Neoplasia

IS - 2

ER -

Role of ErbB4 in breast cancer

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this